(+)-hydrogen tartrate

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (+)-hydrogen tartrate
• 英文别名: D-hydrogen tartrate；L-(+)-hydrogen tartrate；(+) hydrogen tartrate；hydrogen (+)-tartrate；hydrogen tartrate；2,3-dihydroxybutanedioate;hydron
• 化学式: C₄H₄O₆*2H
• 分子量: 150.088
• InChiKey: FEWJPZIEWOKRBE-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -1.2
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  118
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3-(9,10-Didehydro-2-methylthiomethyl-6-n-propyl-8alpha-ergolinyl)-1,1-diethylurea 、 (+)-hydrogen tartrate 以 吡啶 为溶剂， 生成 1,1-Diethyl-3-(2-ethyl-6-n-propyl-8alpha-ergolinyl)-urea
  参考文献：
  名称：

  2-substituted ergolines

  摘要：

  2-取代的麦角酸衍生物，其中C.sub.2 C.sub.3和C.sub.9 C.sub.10代表单键或双键；X为氧或硫；R.sup.2为C.sub.1-10烷基，可选地卤代C.sub.2-10烯基，CH.sub.2 YR.sup.3，CR.sup.12（OR.sup.4）R.sup.5，CH.sub.2-CHR.sup.9-COR.sup.10或COR.sup.12，其中Y为氧或硫，R.sup.3为氢，C.sub.1-4烷基，苯基，C.sub.2-5酰基或苯基C.sub.1-4烷基，R.sup.4为氢或C.sub.2-5酰基，R.sup.5为C.sub.1-9烷基，R.sup.9为COCH.sub.3或COO-C.sub.1-4烷基，R.sup.10为C.sub.1-4烷基或O-C.sub.1-4烷基，R.sup.12为氢或C.sub.1-9烷基；以及它们的酸加合物、异构体和异构体混合物是多巴胺能激动剂，用于治疗帕金森病。

  公开号：

  US05037832A1
• 作为产物：
  描述：

  酒石酸 以 丙酮 为溶剂， 生成 (+)-hydrogen tartrate
  参考文献：
  名称：

  13-Bromo lysergic acid compounds

  摘要：

  本发明涉及一种新的13-溴-麦角酸化合物，化学式为I：##STR1## 其中R.sub.2为异丙基，1或2-甲基丙基或苄基，可用作治疗脑供血不足的药剂。

  公开号：

  US04076715A1
• 作为试剂：
  描述：

  3-(2-[N-(2-(4-chlorophenyl)-ethyl)-N-methylamino]-ethyloxy}-5-(-4-methoxyphenyl)-2-methylpyrazole 、 、 三溴化硼 、 L-酒石酸 在 二氯甲烷 、 甲醇 、 3-{2-[N-(2-(4-chlorophenyl)-ethyl)-N-methylamino]-ethyloxy}-5-(4-hydroxyphenyl)-2-methylpyrazole 、 silica gel 、 title compound 、 乙醚 、 异丙醇 、 (+)-hydrogen tartrate 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 12.0h， 以1.15 g of 3-{2-[N-(2-(4-chlorophenyl)-ethyl)-N-methylamino]-ethyloxy}-5-(4-hydroxyphenyl)-2-methylpyrazole x 1.3 hydrogen tartrate were obtained的产率得到3-{2-[N-(2-(4-chlorophenyl)-ethyl)-N-methylamino]-ethyloxy}-5-(4-hydroxyphenyl)-2-methylpyrazole
  参考文献：
  名称：

  (Phenylalkylaminoalkyloxy)-heteroaryl-compounds, processes and

  摘要：

  本发明涉及一种具有降低心率和/或抗缺血效果的3-(苯基烷基氨基烷氧基)-杂环化合物，以及制备它们的方法和包含它们的药物组合物。所述化合物对应于一般式I ##STR1## 或一般式XXXI ##STR2## 其中取代基的含义在说明中给出。

  公开号：

  US05547967A1

文献信息

• Arylmethylazoles and their salts, processes for their preparation,
  申请人：Hoechst Aktiengesellschaft

  公开号：US04876354A1

  公开（公告）日：1989-10-24

  Arylmethylazoles of the formula I ##STR1## in which Aryl is (substituted) phenyl or naphthyl; Z is CH or N; R.sup.1 and Q are H or alkyl; R.sup.2 is H, alk(en)yl or alkynyl; R.sup.3 and R.sup.4 are H, alkyl or other hydrocarbons; or R.sup.3 and R.sup.4 together are a --(CH.sub.2).sub.2-11 chain or a bridged --(CH.sub.2).sub.4-5 chain, and their acid addition salts, stereoisomers and optically active enantiomers possess outstanding antimycotic and antidepressant activity. They are obtained, inter alia, from arylmethylazoles II ##STR2## which are reacted with a strong base and then with a carbonyl compound III O.dbd.CR.sup.3 R.sup.4 ; thereafter, the product is reacted with the protic acid or with an alkyl halide IV R.sup.2 Hal. If desired, the products are converted to the acid addition salts, or the stereoisomers or optically active enantiomers are resolved.

  Arylmethylazoles的化学式为I，其中Aryl是（取代）苯或萘；Z是CH或N；R.sup.1和Q是H或烷基；R.sup.2是H，烯丙基或炔基；R.sup.3和R.sup.4是H，烷基或其他碳氢化合物；或者R.sup.3和R.sup.4一起是一个--(CH.sub.2).sub.2-11链或一个桥联的--(CH.sub.2).sub.4-5链，它们的酸盐、立体异构体和光学活性对映异构体具有出色的抗真菌和抗抑郁活性。它们可以从Arylmethylazoles II中获得，该化合物与强碱反应，然后与一个醛化合物III O.dbd.CR.sup.3 R.sup.4反应；之后，将产物与质子酸或烷基卤化物IV R.sup.2 Hal反应。如果需要，将产物转化为酸盐，或者将立体异构体或光学活性对映异构体分离。
• 3,7-diazabicyclo(3,3,1)nonane compounds and pharmaceutical compositions
  申请人：Kali-Chemie Pharma GmbH

  公开号：US04912113A1

  公开（公告）日：1990-03-27

  3,7-Diazabicyclo[3,3,1]nonane compounds having valuable heart rate-affecting pharmacological properties corresponding to the Formula I: ##STR1## wherein R.sup.1 is alkyl, cycloalkylalkyl or benzyl, R.sup.2 is lower alkyl, R.sup.3 is lower alkyl, or R.sup.2 and R.sup.3 together form an alkylene chain, and R.sup.4 represents a benzhydryl group, optionally substituted by halogen, lower alkoxy, lower alkyl, hydroxy or trifluoromethyl, or a cinnamyl group optionally substituted by halogen, lower alkyl, lower alkoxy, hydroxy, nitro or trifluoromethyl.

  具有有价值的影响心率药理学特性的3,7-二氮杂双环[3,3,1]壬烷类化合物，对应于公式I： ##STR1## 其中R1是烷基、环烷基烷基或苄基，R2是低碳基，R3是低碳基，或者R2和R3一起形成一个烷基链，而R4代表苯基乙酰基基团，可选地被卤素、低碳氧基、低烷基、羟基或三氟甲基取代，或者是一个肉桂基，可选地被卤素、低碳基、低碳氧基、羟基、硝基或三氟甲基取代。
• Benzophenone glycinamide derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US04007219A1

  公开（公告）日：1977-02-08

  This invention is directed toward pharmacologically active compounds of the formula ##STR1## wherein A represents a nitrogen atom which may be substituted by a methyl, cyclopropylmethyl, di(C.sub.1-4 alkyl)aminoethyl, methoxymethyl or hydroxyethyl group and B represents a carbonyl group or A and B together represent a grouping of the formula ##STR2## in which R.sup.a represents a hydrogen atom or a lower alkyl or hydroxymethyl group and X represents a nitrogen atom or C--R.sup.b wherein R.sup.b represents a hydrogen atom or a lower alkyl or hydroxymethyl group; R represents a halogen atom or a nitro or trifluoromethyl group; R.sup.1 represents a hydrogen atom or a lower alkyl group; R.sup.2 represents an acyl group derived from a naturally occurring amino acid (all such groups which contain an asymmetric carbon atom having the L- or D,L-configuration) and R.sup.3 represents a phenyl, halophenyl or 2-pyridyl group And acid addition salts thereof. Also provided are methods for their preparation and intermediates thereof. These compounds exhibit activity as anticonvulsants, muscle relaxants and sedatives.

  这项发明涉及公式为##STR1##的药理活性化合物，其中A代表氮原子，可被甲基、环丙甲基、二（C.sub.1-4烷基）氨基乙基、甲氧甲基或羟乙基基团取代，B代表羰基基团或A和B一起代表公式##STR2##的基团，其中R.sup.a代表氢原子或较低的烷基或羟甲基基团，X代表氮原子或C--R.sup.b，其中R.sup.b代表氢原子或较低的烷基或羟甲基基团；R代表卤原子或硝基或三氟甲基基团；R.sup.1代表氢原子或较低的烷基基团；R.sup.2代表从天然氨基酸衍生的酰基基团（所有这些基团都包含具有L-或D，L-构型的不对称碳原子）和R.sup.3代表苯基、卤代苯基或2-吡啶基团，以及它们的酸加成盐。还提供了它们的制备方法和中间体。这些化合物表现出抗惊厥、肌肉松弛和镇静活性。
• SELECTIVE EXTRACTION OF POTASSIUM CHLORIDE EMPLOYING TARTARIC ACID AS SAFE, BENIGN AND RECYCLABLE EXTRACTANT
  申请人：Council of Scientific & Industrial Research

  公开号：US20150010448A1

  公开（公告）日：2015-01-08

  Although U.S. Pat. No. 8,182,784 teaches the recovery of potassium chloride from schoenite end liquor (SEL) using dipicrylamine as extractant, and consequently simplifies the recovery of sulphate of potash (SOP) from kainite mixed salt employing the scheme disclosed in U.S. Pat. No. 7,041,268, the hazards associated with this extractant have thwarted practical utilization of the invention. Many other extractants for potash recovery have been disclosed in the prior art but none has been found suitable so far for practical exploitation. It is disclosed herein that the bitartrate ion, and particularly L-bitartrate, precipitates out potassium bitartrate very efficiently from SEL with ca. 90% utilization of the extractant. In contrast, recovery of potassium bi-tartrate from sea bittern directly is relatively much lower. It is further disclosed that this precipitate can be treated with magnesium hydroxide and magnesium chloride to throw out magnesium tartrate with ca. 90% recovery while yielding a nearly saturated solution of potassium chloride which can be utilized for the reaction with schoenite to obtain SOP. It is further demonstrated that the magnesium tartrate can be treated with an appropriate amount of aqueous HCl and added into a subsequent batch of SEL to throw out potassium bitartrate once again which demonstrates the recyclability of the extractant. The overall loss of tartrate over a cycle was ca. 20% but the dissolved tartrate remaining in the K-depleted SEL and KCl solutions can be precipitated out as calcium tartrate from which tartaric acid can be recovered by known methods, curtailing thereby the loss of tartaric acid per kg of KCl to <5 g. It is also demonstrated that through a similar approach, seaweed sap containing ca. 4% KCl can be concentrated to 20-22% KCl, with excellent utilization efficiency of tartaric acid, and this solution can similarly be utilized for SOP preparation. Potassium salts bearing other anions such as sulphate, nitrate, phosphate and carbonate can also be prepared from the isolated potassium bitartrate.

  虽然美国专利号8,182,784教导了使用二硝基苯胺作为萃取剂从锁安石终液中回收氯化钾，并因此简化了使用美国专利号7,041,268所披露的方案从卡因石混合盐中回收硫酸钾（SOP）的过程，但与该萃取剂相关的危险阻碍了该发明的实际利用。许多其他用于钾回收的萃取剂已经在先前的技术中披露，但迄今为止没有发现适合实际开发的萃取剂。本文披露了酒石酸根离子，特别是L-酒石酸，可以非常有效地从锁安石终液中沉淀出酒石酸钾，使用率约为90％。相比之下，直接从海卤水中回收酒石酸钾的效率相对较低。进一步披露了这种沉淀物可以用氢氧化镁和氯化镁处理，回收约90％的酒石酸镁，同时产生一个几乎饱和的氯化钾溶液，可用于与锁安石反应以获得SOP。还表明，可以使用适量的水溶盐酸处理酒石酸镁，并将其加入下一批锁安石终液中，再次沉淀出酒石酸钾，从而证明了萃取剂的可回收性。一个周期内酒石酸的总损失约为20％，但残留在K-贫化的锁安石终液和KCl溶液中的溶解酒石酸可以沉淀出来，从中可以通过已知方法回收酒石酸，从而将每千克KCl的酒石酸损失降至<5克。还表明，通过类似的方法，含约4％ KCl的海藻汁可以浓缩至20-22％ KCl，并具有优异的酒石酸利用效率，这种溶液同样可以用于SOP制备。还可以从分离的酒石酸钾中制备含有其他阴离子（如硫酸根、硝酸根、磷酸根和碳酸根）的钾盐。
• Gmelin Handbuch der Anorganischen Chemie, Gmelin Handbook: Hg: MVol.B3, 6.23, page 1293 - 1298
  作者：

  DOI：——

  日期：——

表征谱图